Find clinical trials

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The study is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

The purpose of this trial is to find out whether a potential new treatment, the trial drug, Lu AF82422, is safe and effective in people living with Multiple Systems Atrophy (MSA). This trial will compare the effects of the trial drug, Lu AF82422, to placebo (inactive medication). Both the trial drug and placebo will be given as an infusion. Whether progression of MSA will be slowed is measured by a rating scale (questionnaire). The trial will also measure the amount of trial drug in participants blood and cerebrospinal fluid. Participants must have a reliable caregiver who will be available throughout the trial to complete caregiver observer questionnaires when carer/observer-reported outcomes are performed. The trial comprises 2 major periods: a 72-week double-blind PCP and an optional dose-blinded 72 week OLE period.

Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.